Autoimmune Diseases / 2013 / Article / Tab 2

Review Article

An Update in the Use of Antibodies to Treat Glioblastoma Multiforme

Table 2

Immunotoxins against gliomas.

ImmunotoxinToxin usedTarget
antigen
Administrative
route
Clinical
trial phase
Number and
type of tumor
OutcomeAdverse effectReferences

IL-4(38-37)-
PE38KDEL
(38-37)
PE38KDEL
IL-4R
Intratumoral
(CED)
I/II31 (25 GBM and 6 AA)Median survival 8.2 months; six-month survival was 52%Headache, seizure,
weakness, dysphasia, and hydrocephalus
[2123]

IL13-PE38QQRPE38QQRIL-13RIntratumoral
(CED)
I/II/IIIPhase II, 51 (46 GBM, 3 AA, other 2); Phase III, 296 recurrent GBMInfusion MTIC was 0.5 μg/mL; up to 6 d well tolerated; median survival 42.7 weeks (95% CI, 35.6–55.6) for GBM in Phase II and 36.4 weeks in Phase III, comparable to Gliadel WaferHeadache,
dysphasia, seizure,
weakness, and
pulmonary embolism
[2426]

TP-38PE-38TGF- Intratumoral
(CED)
I20 (17 GBM, other 3)Median survival 28 weeks (95% CI, 4.1–45.1)Hemiparesis, fatigue, headache, and dysphasia[27, 28]

Tf-CRM107DT-CRM107TfIntratumoral
(CED)
I/II44 (GBM, AA)Median survival 37 weeks, (95% CI, 26–49); 5/34 CR, 7/34 PR, response rate 35% (95% CI, 20–54; )Seizure, cerebral edema [29]

GBM: glioblastoma multiforme; AA: anaplastic astrocytoma; TGF: transforming growth factor; CED: convection-enhanced delivery; MTIC: maximum-tolerated infusate concentration; CI: confidence interval; Tf: transferrin; CR: complete response; PR: partial responders; RR: radiographic response.

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.